ArticleNPJ vaccines2020
Lipid moieties of
Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management.Infection · 2026Review
- Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach.Molecular diversity · 2026Article
- Immunogenicity Evaluation of Six Key Antigens ofVaccines · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- An mRNA Vaccine Targeting the C-Terminal Region of P1 Protein Induces an Immune Response and Protects AgainstInternational journal of molecular sciences · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- Advances in adhesion-related pathogenesis inFrontiers in microbiology · 2025Review
- Detection of Contagious Caprine Pleuropneumonia in Three Provinces of Iran: 2017-2018.Archives of Razi Institute · 2024Article
- Review
- Research of recombinant influenza A virus as a vector for Mycoplasma pneumoniae P1a and P30a.Immunity, inflammation and disease · 2024Article
- Exploring the pathogenetic mechanisms ofExperimental and therapeutic medicine · 2024Review
- Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae.Current microbiology · 2022Review
- B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs.NPJ vaccines · 2022Article
- Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease.NPJ vaccines · 2022Article
- Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.Frontiers in cellular and infection microbiology · 2022Review
- Review
- Lymphocyte Activation Gene-3 Regulates Dendritic Cell Metabolic Programing and T Cell Priming Function.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Contagious Bovine and Caprine Pleuropneumonia: a research community's recommendations for the development of better vaccines.NPJ vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine-enhanced disease (VED) occurs as a result of vaccination followed by infection with virulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.